VNDA Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

59.28M

+11.45%

-1.325

+1556.25%

61.47M

+22.83%

-0.427

-14.67%

64.93M

+23.47%

-0.400

-13.04%

Estimates Revision

The market is revising Downward the revenue expectations for Vanda Pharmaceuticals Inc. (VNDA) for FY2025, with the revenue forecasts being adjusted by -2.32% over the past three months. During the same period, the stock price has changed by 34.68%.

Revenue Estimates for FY2025

Revise Downward

-2.32%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+25.41%

In Past 3 Month

Stock Price

Go Up

+34.68%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast VNDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VNDA is 15.50 USD with a low forecast of 11.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

11.00

Averages

15.50

High

20.00

Current: 0.000

Low

11.00

Averages

15.50

High

20.00

H.C. Wainwright

maintain

$22

2026-01-08

New

Reason

H.C. Wainwright

Price Target

$22

2026-01-08

New

maintain

Reason

H.C. Wainwright notes that Vanda Pharmaceuticals announced that it has received a decision letter from the FDA's Center for Drug Evaluation and Research concluding that the supplemental New Drug Application for HETLIOZ - tasimelteon - for the treatment of jet lag disorder cannot be approved in its current form. In the firm's view, the rejection of tasimelteon constitutes only a minor setback and may not mark the end of dialogue over the compound in this indication. Furthermore, Wainwright draws investors' attention to the fact that its valuation assessment did not include any contribution from sales of tasimelteon in treatment of jet lag. Accordingly, the firm reiterates a Buy rating and a price target of $22 on the shares.

H.C. Wainwright

Buy

maintain

$20 -> $22

2026-01-05

New

Reason

H.C. Wainwright

Price Target

$20 -> $22

2026-01-05

New

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Vanda Pharmaceuticals to $22 from $20 and keeps a Buy rating on the shares. The firm cites the addition of tradipitant sales into the model following the approval for the treatment of motion sickness for the target boost.

Cantor Fitzgerald

Olivia Brayer

Overweight

maintain

$11

2025-12-31

Reason

Cantor Fitzgerald

Olivia Brayer

Price Target

$11

2025-12-31

maintain

Overweight

Reason

Cantor Fitzgerald analyst Olivia Brayer keeps an Overweight rating on Vanda Pharmaceuticals with an $11 price target after the FDA approved Nereus for the prevention of motion sickness. The motion sickness opportunity could add upside to estimates, but the bigger implication is that the approval could have an "important look-through" for Vanda's GLP-1 nausea program, which begins Phase 3 in 2026, the analyst tells investors in a research note. Cantor views Nereus' label as "fairly broad." Vanda has talked about motion sickness as a several hundred million peak sales opportunity, the firm adds.

B. Riley

Buy

maintain

$11 -> $14

2025-12-31

Reason

B. Riley

Price Target

$11 -> $14

2025-12-31

maintain

Buy

Reason

B. Riley raised the firm's price target on Vanda Pharmaceuticals to $14 from $11 and keeps a Buy rating on the shares after the FDA approved Nereus for prevention of vomiting induced by motion sickness. The news supports the view that Vanda is an "ongoing turnaround story" trading at an "excessive discount" heading into two more potential approvals within the next 12 months, the analyst tells investors in a research note. Riley says that while the approval could unlock over $100M in peak revenue, the greater significance is in the implications for tradipitant approval in GLP-1 related nausea.

Jefferies

Hold

maintain

2025-12-31

Reason

Jefferies

Price Target

2025-12-31

maintain

Hold

Reason

Jefferies raised the firm's price target on Vanda Pharmaceuticals to $7.50 from $5 and keeps a Hold rating on the shares following the FDA approval of Nereus. The company believes Nereus could become a $100M-$300M opportunity for the prevention of vomiting caused by motion, the analyst tells investors in a research note. The firm awaits the drug's price but expects a pricing premium to the over-the-counter alternatives like Dramamine. Nereus' approval supports the drug's acute use for other indications, such as GLP1-associated vomiting and nausea, adds Jefferies.

Truist

Joon Lee

Hold

maintain

$20 -> $36

2025-11-10

Reason

Truist

Joon Lee

Price Target

$20 -> $36

2025-11-10

maintain

Hold

Reason

Truist analyst Joon Lee raised the firm's price target on AnaptysBio (ANAB) to $36 from $20 and keeps a Hold rating on the shares. The company's Q3 benefitted from $50M in Jemperli milestones and growing royalties, with another $75M in milestones expected in Q4, the analyst tells investors in a research note. Near-term catalysts for the stock include Phase 2 UC update in November-December and Vanda's (VNDA) imsidolimab BLA submission in Q4 for GPP, which is tied to milestones for AnaptysBio, the firm added.

Valuation Metrics

The current forward P/E ratio for Vanda Pharmaceuticals Inc (VNDA.O) is -3.33, compared to its 5-year average forward P/E of -19.53. For a more detailed relative valuation and DCF analysis to assess Vanda Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-19.53

Current PE

-3.33

Overvalued PE

156.78

Undervalued PE

-195.83

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

4.79

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

11.49

Undervalued EV/EBITDA

-1.92

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

1.96

Current PS

1.90

Overvalued PS

2.79

Undervalued PS

1.13

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

VNDA News & Events

Events Timeline

No data

News

9.0

01-08Newsfilter

Vanda Pharmaceuticals' HETLIOZ® Faces Delay as FDA Rejects Current Efficacy Evidence

9.0

01-06Newsfilter

Vanda Pharmaceuticals Receives FDA Approval for Motion Sickness Drug, Analysts Raise Price Targets

9.0

01-06Benzinga

Vanda Pharmaceuticals' Nereus Approved by FDA as First New Motion Sickness Drug in 40 Years

People Also Watch

Frequently Asked Questions

What is Vanda Pharmaceuticals Inc (VNDA) stock price today?

The current price of VNDA is 7.34 USD — it has decreased -14.05 % in the last trading day.

What is Vanda Pharmaceuticals Inc (VNDA)'s business?

Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company’s commercial portfolio consist of three products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) and PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Tradipitant, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.

What is the price predicton of VNDA Stock?

What is Vanda Pharmaceuticals Inc (VNDA)'s revenue for the last quarter?

Vanda Pharmaceuticals Inc revenue for the last quarter amounts to 56.26M USD, increased 18.06 % YoY.

What is Vanda Pharmaceuticals Inc (VNDA)'s earnings per share (EPS) for the last quarter?

Vanda Pharmaceuticals Inc. EPS for the last quarter amounts to -0.38 USD, increased 322.22 % YoY.

What changes have occurred in the market's expectations for Vanda Pharmaceuticals Inc (VNDA)'s fundamentals?

How many employees does Vanda Pharmaceuticals Inc (VNDA). have?

Vanda Pharmaceuticals Inc (VNDA) has 368 emplpoyees as of January 09 2026.

What is Vanda Pharmaceuticals Inc (VNDA) market cap?

Today VNDA has the market capitalization of 433.77M USD.